Trump Threatens to Annex Greenland; Denmark to Invest $13.8 Billion in Defense
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: CNBC
- Market Reaction: European stocks showed mixed performance on Wednesday morning, with the Stoxx 600 index little changed, reflecting market jitters over Trump's threat to annex Greenland, which could impact investor confidence.
- Defense Investment: Danish Defense Minister announced an investment of 88 billion Danish kroner (approximately $13.8 billion) to rearm Greenland in response to the serious security situation, highlighting the importance of regional security.
- Corporate Dynamics: Logistics firm InPost's stock fell 5.8%, making it the worst performer in the Stoxx 600 after gaining 28% on Tuesday due to an acquisition proposal, indicating volatility in investor sentiment.
- Legal Action: Bayer's shares rose 1.1% after it filed a patent infringement lawsuit against Pfizer, BioNTech, and Moderna, alleging unauthorized use of its mRNA technology in their COVID-19 vaccines, which may affect the market positions of these companies.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.890
Low
24.00
Averages
28.56
High
35.00
Current: 25.890
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
